Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Otonomy Inc    OTIC

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
13.1(c) 12.25(c) 13.15(c) 13.1(c) 12.85(c) Last
150 513 159 699 231 639 117 846 130 464 Volume
-2.60% -6.49% +7.35% -0.38% -1.91% Change
More quotes
Financials ($)
Sales 2017 3,81 M
EBIT 2017 -101 M
Net income 2017 -101 M
Finance 2017 71,0 M
Yield 2017 -
Sales 2018 22,3 M
EBIT 2018 -95,9 M
Net income 2018 -95,5 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 83,5x
Capi. / Sales2018 17,4x
Capitalization 389 M
More Financials
Company
Otonomy, Inc. engages in the research, development, and manufacture of biopharmaceutical products.The firm's portfolio includes therapeutics for diseases and disorders of the ear such as otitis media, acute otitis externa, balance disorders, Ménière's disease, tinnitus, cisplatin-induced hearing... 
More about the company
Surperformance© ratings of Otonomy Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on OTONOMY INC
03/02 OTONOMY : reports 4Q loss
03/02 Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provi..
03/02 OTONOMY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
03/02 OTONOMY, INC. : Results of Operations and Financial Condition, Financial Stateme..
02/28 Otonomy to Present at Cowen and Company Health Care Conference
02/24 Otonomy to Report Fourth Quarter and Full Year 2016 Financial Results and Pro..
01/23 OTONOMY : Enrolls Patients for Phase 2 Trial of OTO-104 for Prevention of Hearin..
01/19 Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as ..
01/13 OTONOMY, INC. : Results of Operations and Financial Condition, Financial Stateme..
01/09 Otonomy Provides Corporate and Product Pipeline Update
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Latest Tweets
03/17#TrendReversalUp $OTIC OTONOMY INC #TradeIdeas via ?  
03/11SunTrust Banks Comments on Otonomy Inc’s FY2021 Earnings $OTIC  
03/08Otonomy (OTIC) Presents At Cowen and Company 37th Annual Health Care Conferen.. 
03/08Want the latest analyst ratings on $HEES $OTIC $TNB $GBCI $GTXI? Get Them Del.. 
03/03$OTIC: Otonomy reports Q4, issues guidance  
More tweets
Qtime:8
News from SeekingAlpha
03/08 Otonomy (OTIC) Presents At Cowen and Company 37th Annual Health Care Conferen..
03/02 Otonomy's (OTIC) CEO David Weber on Q4 2016 Results - Earnings Call Transcrip..
03/02 Otonomy beats by $0.05, misses on revenue
01/19 Otonomy commences mid-stage study of OTO-104 to prevent hearing loss in cance..
01/17 OTONOMY : A Core Buy In Biotech
Advertisement
Chart OTONOMY INC
Duration : Period :
Otonomy Inc Technical Analysis Chart | OTIC | US68906L1052 | 4-Traders
Full-screen chart
Technical analysis trends OTONOMY INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 28,6 $
Spread / Average Target 123%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David A. Weber President, Chief Executive Officer & Director
Jay B. Lichter Chairman
Paul E. Cayer CFO, Chief Business & Principal Accounting Officer
Robert Michael Savel Chief Technical Officer
Dean Hakanson Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
OTONOMY INC-19.18%389
AMGEN, INC.13.36%122 060
CELGENE CORPORATION6.59%95 986
GILEAD SCIENCES, INC.-5.73%88 240
REGENERON PHARMACEUTIC..1.61%39 568
ACTELION LTD24.44%29 804
More Results